Sequence information
Variant position: 695 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1863 The length of the canonical sequence.
Location on the sequence:
ATGAKKSNKPNEQTSKRHDS
D TFPELKLTNAPGSFTKCSNT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ATGAKKSNKPNEQTSKRHDSD TFPELKLTNAPGSFTKCSNT
Gorilla ATGAKKSNKPNEQTSKRHDSD TFPELKLTNAPGSFTNCSNT
AGRAKKSSKPGEQINKRLASH AFPELTLTNVSGFFANYSSS
Rhesus macaque ATGAKKSNKPNEQTSKRHASD TFPELKLTKVPGSFTNCSNT
Chimpanzee ATGVKKSNKPNEQTSKRHDSD TFPELKLTNAPGSFTNCSNT
Mouse AADAKK-NEPNEHIRKRRASD AFPEEKLMNKAGLLTSCSSP
Rat AADAKK-NEPNEHIRKRSASD AFPEEKLMNKAGLLTSCSSP
Bovine TAGAKN-NKTYEQINKRLASD AFPELKLTNTPGYFTNCSS-
Caenorhabditis elegans AT-----KQPVE-----LQSR VFPLEKL-------------
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1863
Breast cancer type 1 susceptibility protein
Region
654 – 709
Disordered
Compositional bias
676 – 698
Basic and acidic residues
Modified residue
694 – 694
Phosphoserine
Modified residue
708 – 708
Phosphoserine
Alternative sequence
64 – 1863
Missing. In isoform 2.
Alternative sequence
224 – 1365
Missing. In isoform 5.
Alternative sequence
264 – 1366
Missing. In isoform 3 and isoform 6.
Literature citations
A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P.; van der Gulden H.; van der Heijden I.; Drost R.; Klijn C.N.; Prasetyanti P.; Pieterse M.; Wientjens E.; Seibler J.; Hogervorst F.B.; Jonkers J.;
Cancer Discov. 3:1142-1155(2013)
Cited for: CHARACTERIZATION OF VARIANTS BC PHE-4; THR-18; GLN-45; GLY-61; GLY-64; TYR-67; LYS-132; HIS-142; PHE-147; PRO-165; TRP-170; TYR-186; ILE-191; MET-231; VAL-245; VAL-246; LEU-271; PHE-668; ASN-695; LEU-798; TYR-810; LYS-826; GLN-841; HIS-856; ASN-1101; ASN-1140; GLY-1140; LYS-1214; LYS-1236; SER-1267; VAL-1282; SER-1297 DEL; ARG-1301; LYS-1346; ILE-1378; VAL-1400; PRO-1407; THR-1411; GLY-1443; GLY-1448; CYS-1486; MET-1534; PRO-1589; THR-1628; PRO-1651; PHE-1651; PHE-1655; ARG-1686; GLN-1686; VAL-1688 DEL; ILE-1691; TRP-1699; GLN-1699; GLU-1706; ALA-1706; GLU-1708; CYS-1718; ALA-1720; LYS-1735; ALA-1736; GLY-1739; VAL-1739; GLN-1746; THR-1753; PRO-1764; SER-1767; VAL-1770; CYS-1782; THR-1789; ASP-1794; ASP-1804; ARG-1812; ARG-1837 AND LEU-1862; VARIANTS CYS-105; CYS-866; ALA-1060; LYS-1250 AND ILE-1652;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.